Abstract
Introduction microRNAs (miRs) are a class of small non-coding RNAs whose mature products are ~22 nucleotides long. They negatively regulate gene expression at the post-transcriptional and/or translational level. They were first discovered by Ambros and colleagues in 1993
in C.elegans and were shown to be abundantly expressed in viruses [2] , plants [3] and animals [4] . To [5] [6] [7] . Many miRs show sequence and function conservation between distantly related organisms, suggesting that this class of small RNAs is an integral part of essential cellular processes [8] . For example, was initially discovered to be responsible for the developmental transition of L4 lavae to the adult cell fates [9] in C.elegans. It was later found to be evolutionarily conserved, regulating development in Drosophila, zebrafish, annelids, mollusks [8] and mouse [10] [39] [40] [41] , tongue [42] , nose and pharynx [43] , liver [44] [45] [46] [47] , the gastro-intestinal system (esophageal [48] , gastric [49] , pancreatic [50, 51] and colorectal cancers [52, 53] ) as well as the genitourinary system (cervical [54] , ovarian [55, 56] and prostate [57, 58] [44] and programmed cell death 4 (PDCD4) [61] [6] , PicTar [110] and TargetScan [111] [113, 114] , suggesting the classification of cancer-related genes into oncogenes or tumour suppressors may be an over-simplification. Figure 1 [114, 115] ). In the following discussion, we will discuss some pro-apoptotic miRs, anti-apoptotic miRs and miRs that regulate both proliferation and apoptosis.
miR and apoptosis

Apoptosis is the intrinsic cellular mechanism to eliminate cells that are damaged or transformed. Deregulation of apoptosis is an important step in cancer as it allows the genetically unstable cells to survive and accumulate further mutations that eventually lead to tumourigenesis. As cancer cells are mostly characterized by increased cell proliferation and decreased cell death, cancerimplicated genes have conventionally been classified into two groups. One group, the oncogenes, up-regulates proliferation and down-regulates apoptosis, whereas the other group, the tumour suppressor genes, performs just the opposite function. Indeed, pro-apoptotic genes such as p53 are frequently inactivated whilst anti-apoptotic genes such as B-cell CLL/lymphoma 2 (BCL2) are frequently over-activated in cancer progression. However, recent evidence has shown that up-regulation of MYC and E2F oncogenes can increase both cell proliferation and apoptosis
summarizes our current knowledge of miRs implicated in cell-proliferation and apoptosis, revealing that the miR-regulatory network is just as complicated as its protein-coding counterparts. Some miRs, such as miR-29b and miR-15-16, were found to affect only the apoptotic pathway, whereas others including let-7/miR-98 and miR-17-92 play roles in both the apoptotic and cell-proliferation pathways (see review
The pro-apoptotic miRs targeting the BCL2 family of genes
The miR-15-16 cluster induces apoptosis by targeting the important anti-apoptotic factor BCL2 at the post-transcriptional level [66] . [116] and in the mouse model [117] . miR-21 directly targets PTEN whose down-regulation will release its inhibition on protein kinase B (PKB) resulting in significantly reduced apoptosis in cancer cells (Fig.1) . miR-21 also targets PDCD4 [61] , a pro-apoptotic gene frequently down-regulated in hepatocellular carcinoma(HCC) [118] . Interestingly, miR-21 was also reported to be up-regulated in HCC (Table 1) . This suggests that miR-21 can inhibit apoptosis through both PTEN and PDCD4. Recently, miR-21 was reported to target important tumour suppressor genes including tropomyosin 1 (TPM1) [72] and serpin peptidase inhibitor, clade B (ovalbumin), member 5 (SERPINB5) [73] 
It was proposed to function as a tumour suppressor by keeping cell growth in check under normal physiological conditions. Like many tumour suppressors, this miR cluster is found to be frequently deleted in B-cell chronic lymphocytic leukaemia (CLL), resulting in its down-regulation in more than 68% of the CLL cases [28]. The miR-15-16 cluter is also reported to be down-regulated in pituitary adenoma [34] and prostate carcinoma [57]. Hence in these cancers, miR-15-16 expression is preferentially down-regulated to favour cancer development by inhibiting apoptosis (Fig.1). In a recent study, which utilized expression microarray to investigate the effects of miR-15a and miR-16-1 on the transcriptome and proteome of MEG-01 leukaemic cells, genes (e.g. MCL1, ETS1 and JUN) that directly or indirectly play a role in apoptosis and cell-cycle were found to be significantly differentially expressed in these cells. Another miR, miR-29b, which is down-regulated in lung and
The anti-apoptotic miR-21 targets PTEN and PDCD4
miR-21 is the most consistently up-regulated miR across many cancer types (Table 1). miR-21 was first implicated as an antiapoptotic factor by the observation that knock-down of miR-21 increased apoptotic cell death in human glioblastoma cells
miR-210 decreases proapoptotic signalling in a hypoxic environment
Hypoxia-regulated microRNAs such as miR-210 is induced in response to low oxygen and play a role in cell survival by decreasing caspase activation, the central components of apoptotic signalling [119]. As hypoxia is an important feature of tumour microenvironment, it is of interest to note that miR-210 is also
Fig. 1 Diagrammatic representation of the roles of miRs in the regulation of cell proliferation and apoptosis. Red colour indicates a general up-regulation of miRs in cancers and green colour indicates a general down-regulation of miRs in cancer.
over-expressed in many major tumour types ( 
Other miRs implicated in apoptosis
There are a number of other miRs that may potentially play roles in regulating apoptosis in cancer. For example, miR-155 is frequently over-expressed in many cancers and targets the tumour protein p53 inducible nuclear protein 1 (TP53INP1) [91] . TP53INP1 was reported to be a positive regulator of p53-dependent apoptosis by enhancing Ser46 phosphorylation of p53 which in turn induced p53-regulated apoptosis-inducing protein 1(p53AIP1) expression and subsequent apoptotic cell death [125] . Hence, over-expression of miR-155 in cancers will inhibit TP53INP1 expression and attenuate apoptotic cell death induced by TP53INP1. In contrast, miR-127 was reported to target B-cell CLL/lymphoma 6 (BCL6) [84] to potentially increase TP53-dependent apoptosis by disrupting the negative regulatory feedback loop between BCL6 and TP53 [126, 127] . However, our understanding of the rationale behind this deregulation in cancer remains unclear. 
Conclusion
